Update on the treatment of disseminated intravascular coagulation

Hematology

Volumn 9, Issue 2, 2004, Pages 81-85

  Franchini, Massimo ^a   Manzato, Franco ^b  

^a OSPEDALE POLICLINICO   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Anticoagulation; AT III; Disseminated intravascular coagulation; Fibrinolytic inhibitors; Protein C; Replacement therapy

Indexed keywords

ACTIVATED PROTEIN C; AMINOCAPROIC ACID; ANTICOAGULANT PROTEIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7A INHIBITOR; CD14 ANTIGEN; FIBRIN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT HIRUDIN; RECOMBINANT INTERLEUKIN 10; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RETINOIC ACID; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CRYOPRECIPITATE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTOXEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; THROMBOCYTE TRANSFUSION;

EID: 2542542737     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/1024533042000205504     Document Type: Review

References (59)

1. Bick, R.L. (2003) "Disseminated intravascular coagulation. Current concepts of etiology, pathophysiology, diagnosis, and treatment", Hematol. Oncol. Clin. N. Am. 17, 149-176.
2. Levi, M. and ten Cate, H. (1999) "Disseminated intravascular coagulation", N. Engl. J. Med. 341, 586-592.
3. Levi, M., de Jonge, E., Van der Poll, T. and ten Cate, H. (1999) "Disseminated intravascular coagulation", Thromb. Haemostasis 82, 695-705.
4. Levi, M., de Jonge, E. and Meijers, J. (2002) "The diagnosis of disseminated intravascular coagulation", Blood Rev. 16, 217-223.
5. Riewald, M. and Riess, H. (1998) "Treatment options for clinically recognized disseminated intravascular coagulation", Semin. Thromb. Hemost. 24, 53-59.
6. Bick, R.L. (1996) "Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response", Semin. Thromb. Hemost. 22, 69-88.
7. Mammen, E.F. (2000) "Disseminated intravascular coagulation (DIC)", Clin. Lab. Sci. 13, 239-245.
8. Yu, M., Nardella, B.S. and Pechet, L. (2000) "Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis", Crit. Care Med. 28, 1777-1780.
9. Faust, S.N., Heyderman, R.S. and Levin, M. (2000) "Disseminated intravascular coagulation and purpura fulminans secondary to infection", Best Pract. Res. Clin. Haematol. 13, 179-197.
10. Letsky, E.A. (2001) "Disseminated intravascular coagulation", Best Pract. Res. Clin. Obstet Gynaecol. 4, 623-644.
11. Carey, M.J. and Rogers, G.M. (1998) "Disseminated intravascular coagulation: clinical and laboratory aspects", Am. J. Hematol. 59, 65-73.
12. Rocha, E., Paramo, J.A., Montes, R. and Panizo, C. (1998) "Acute generalized, widespread bleeding. Diagnosis and management", Haematologica 83, 1024-1037.
13. Levi, M., de Jonge, E., van der Poll, T. and ten Cate, H. (2000) "Novel approach to the management of disseminated intravascular coagulation", Crit. Care Med. 28(Suppl.), 20-24.
14. Wheeler, A.P. and Bernard, G.R. (1999) "Treating patients with severe sepsis", N. Engl. J. Med. 340, 207-214.
15. Levi, M., de Jonge, E. and van der Poll, T. (2002) "Therapeutic intervention in disseminated intravascular coagulation: have we made any progress in the last millennium?", Blood Rev. 16, 29-34.
16. van der Poll, T. (2001) "Immunotherapy of sepsis", Lancet Infect. Dis. 1, 165-174.
17. Levi, M., de Jonge, E. and van der Poll, T. (2001) "Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation" , Crit. Care Med. 29, 90-94.
18. Levi, M., de Jonge, E. and van der Poll, T. (2001) "Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies", Semin. Thromb. Hemost. 27, 569-575.
19. Feinstein, D.I. (1982) "Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy" , Blood 60, 284-287.
20. Hoyle, C.F., Swisky, D.M., Freedman, L. and Hayhoe, G.F.J. (1988) "Beneficial effect of heparin in the management of patients with APL", Br. J. Hematol. 68, 283-289.
21. Goldberg, M., Ginsburg, D., Mayer, R., et al. (1987) "Is heparin necessary during induction chemotherapy for patients with acute promyelocytic leukemia?", Blood 69, 187-191.
22. Rodeghiero, F., Avvisati, G., Castaman, G., Barbui, T. and Mandelli, F. (1990) "Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients", Blood 75, 2112-2117.
23. Sakuragawa, N., Hasegawa, H., Maki, M., Nakagawa, M. and Nakashima, M. (1993) "Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double blind trial in comparison with heparin", Thromb. Haemostasis 72, 475-500.
24. Majumdar, G. (1996) "Idiopathic chronic DIC controlled with low-molecular-weight heparin", Blood Coagul. Fibrinol. 7, 97-98.
25. Pernerstorfer, T., Hollenstein, U. and Hansen, J.B. (1999) "Heparin blunts endotoxin-induced coagulation activation", Circulation 100, 2485-2490.
26. Abraham, E., Reinhart, K. and Demeyer, I. (2003) "Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial", J. Am. Med. Assoc. 290, 238-247.
27. Munoz, M.C., Montes, R., Hermida, J., et al. (1999) "Effect of the administration of recombinant hyrudin and/or tissue-plasminogen activator (T-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits", Br. J. Haematol. 105, 117-122.
28. Pernerstorfer, T., Hollenstein, U., Hansen, J.B., et al. (2000) "Lepirudiun blunts endotoxin-induced coagulation activation", Blood 95, 1729-1734.
29. De Jonge, E., van der Poll, T., Kesecioglu, J. and Levi, M. (2001) "Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience", Semin. Thromb. Hemost. 27, 667-674.
30. Giudici, D., Baudo, F., Palareti, G., Ravizza, A., Ridolfi, L. and D'Angelo, A. (1999) "Antithrombin replacement in patients with sepsis and severe shock", Haematologica 84, 452-460.
31. Okajima, K. and Uchiba, M. (1998) "The anti-inflammatory properties of anti-thrombin III: new therapeutic implications", Semin. Thromb. Hemost. 24, 27-32.
32. Inthorn, D., Hoffman, J., Hartl, W., et al. (1998) "Effect of antithrombin III supplementation on inflammatory response in patients with sever sepsis", Shock 10, 90-96.
33. Kessler, C.M., Tang, Z., Jacobs, H.M. and Szymanski, L.M. (1997) "The suprapharmacological dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity", Blood 89, 4393-4401.
34. Fourrier, F., Jourdain, M. and Tournoys, A. (2000) "Clinical trial results with antithrombin III in sepsis", Crit. Care Med. 28, S38-S43.
35. Eisele, B., Lamy, M., Thijs, L.G., et al. (1998) "Antithrombin III in patients with severe sepsis: a randomized placebo-controlled, double-blind multicenter trial plus meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis", Intensive Care Med. 24, 663-672.
36. Baudo, F., Caimi, T.M., de Cataldo, F., et al. (1998) "Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or post-surgical complications: a controlled, double blind, randomized multicenter study", Intensive Care Med. 24, 336-342.
37. Warren, B.L., Eid, A., Singer, P., et al. (2001) "High-dose antithrombin III in severe sepsis: a randomized controlled trial", J. Am. Med. Assoc., 1869-1878.
38. Taylor, F.B., Chang, A., Esmon, C.T., et al. (1987) "Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon", J. Clin. Investig. 79, 918-925.
39. Maruyama, I. (1999) "Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation", Thromb. Haemostasis 82, 718-721.
40. Bernard, G.R., Hartman, D.L., Helterbrand, J.D. and Fisher, C.J. (1998) "Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with sever sepsis", Crit. Care Med. 27, S4.
41. Bernard, G.R., Vincent, J.L., Laterre, P.F., et al. (2001) "Efficacy and safety of recombinant human activated protein C for severe sepsis", N. Engl. J. Med. 344, 699-709.
42. Aoki, N., Matsuda, T., Saito, H., et al. (2002) "A comparative double-blind randomized trial of activated protein C and unfractioned heparin in the treatment of disseminated intravascular coagulation", Int. J. Hematol. 75, 540-547.
43. Dhainaut, J.F., Laterre, P.F., Janes, J.M., et al. (2003) "Drotrecogin alfa (activated) in treatment of severe sepsis patients with multiorgan dysfunction: data from the PROWESS trial", Intensive Care Med. 29, 894-903.
44. Vincent, J.L., Angus, D.C., Artigas, A., et al. (2003) "Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial", Crit. Care Med. 31, 834-840.
45. Levi, M., de Jonge, E. and van der Poll, T. (2002) "Recombinant human activated protein C (Xigris)", Int. J. Clin. Pract. 56, 542-545.
46. Pastores, S.M. (2003) "Drotrecogin alfa (activated): a novel therapeutic strategy for sever sepsis", Postgrad. Med. J. 79, 5-10.
47. Warren, H.S., Suffredini, A.F., Eichacker, P.Q. and Munford, R.S. (2002) "Risks and benefits of activated protein C treatment for severe sepsis", N. Engl. J. Med. 347, 1027-1030.
48. Bajaj, M.S. and Bajaj, S.P. (1997) "Tissue factor pathway inhibitor: potential therapeutic applications", Thromb. Haemostasis 78, 471-477.
49. Abraham, E. (2000) "Tissue factor inhibition and clinical trials results of tissue factor pathway inhibitor in sepsis", Crit. Care Med. 28, S31-S33.
50. De Jonge, E., Dekkers, P.E., Creasey, A.A., et al. (2000) "Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia", Blood 95, 1124-1129.
51. Abraham, E., Reinhart, K. and Svoboda, P. (2001) "Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study", Crit. Care Med. 29, 2081-2089.
52. Avvisati, G., ten Cate, J.W., Buller, H.R. and Mandelli, F. (1989) "Tranexamic acid for control of hemorrhage in acute promyelocytic leukemia", Lancet 2, 122-124.
53. Norman, K.E., Cotter, M.J. and Stewart, B.J. (2003) "Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation", Blood 101, 921-928.
54. Pajkrt, D., van der Poll, T., Levi, M., et al. (1997) "Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia", Blood 89, 2701-2705.
55. Reinhart, K. and Waheedullah, K. (2001) "Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned", Crit. Care Med. 29, S121-S125.
56. Branger, J., van den Blink, B., Weijer, S., et al. (2003) "Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia", Blood 101, 4446-4448.
57. Verbon, A., Meijers, J.C. and Spek, C.A. (2003) "Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans", J. Infect Dis. 187, 55-61.
58. Moons, A.H., Peters, R.J., Cate, H., Bauer, K.A., Vlasuk, G.P., Buller, H.R. and Levi, M. (2002) "Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees", Thromb. Haemostasis 88, 627-631.
59. Biemond, B.J., Levi, M., ten Cate, H., et al. (1995) "Complete inhibition of endotoxin induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa", Thromb. Haemostasis 75, 223-230.